Patient with Metastatic Pancreatic Cancer Remains Disease-Free for More Than Three Years After Experimental Treatment

Researchers from Columbia University and Brown University have reported encouraging results from an early clinical study of a new treatment approach for metastatic pancreatic cancer. The findings were published in the journal Nature Communications.

The study involved 11 patients with newly diagnosed metastatic pancreatic cancer who had not previously received treatment. They were given a four-drug combination consisting of motixafortide, which blocks the CXCR4 receptor; the immunotherapy drug cemiplimab; and the chemotherapy agents gemcitabine and nab-paclitaxel.

One patient achieved a particularly remarkable response. The tumor responded so well to treatment that doctors were able to perform surgery. Examination of the removed tissue found no viable cancer cells, indicating a complete pathological response.

The patient has remained free of detectable disease for more than three years since starting treatment and for more than two years since surgery, without receiving any additional therapy. Such a response is considered extremely rare in metastatic pancreatic cancer.

Among all participants, median progression-free survival was 9.7 months, while median overall survival was 10.1 months. By comparison, with standard treatment using gemcitabine and nab-paclitaxel, these figures are typically around three to four months and six months, respectively.

The researchers believe the key to the results lies in targeting not only the tumor itself but also its surrounding microenvironment. Pancreatic cancer is surrounded by tissues and immune cells that create a strongly immunosuppressive environment, effectively protecting the tumor from attack by the immune system.

The scientists focused on the CXCR4/CXCL12 signaling pathway, which plays a role in creating this protective environment. First, motixafortide blocks CXCR4 and alters the tumor microenvironment. Immunotherapy and chemotherapy are then administered to attack the cancer. Animal experiments showed that the sequence in which the drugs are given is critical to the effectiveness of the approach.

The new strategy targets several mechanisms that help protect pancreatic tumors simultaneously.

The study also provided insights into why even initially effective treatment can eventually stop working.

Using single-cell analysis of blood and tumor tissue samples, the researchers found that the therapy does indeed alter the immune environment surrounding the tumor. Over time, however, T cells that attack cancer cells can enter a functionally exhausted state and lose their ability to sustain an effective immune response.

The researchers stress that the findings are preliminary and are based on a very small group of patients. Larger clinical trials will be needed to determine whether this treatment strategy can provide consistent benefits for people with metastatic pancreatic cancer.

Follow NEWS.am Medicine on Facebook and Twitter